Literature DB >> 24151752

Prevention and management of potential adverse events during transapical aortic valve replacement.

Ludwig K von Segesser1, Gino Gerosa, Michael A Borger, Enrico Ferrari.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Transapical transcatheter aortic valve replacement (TAVR) is a new minimally invasive technique with a known risk of unexpected intra-procedural complications. Nevertheless, the clinical results are good and the limited amount of procedural adverse events confirms the usefulness of a synergistic surgical/anesthesiological management in case of unexpected emergencies.
METHODS: A review was made of the authors' four-year database and other available literature to identify major and minor intra-procedural complications occurring during transapical TAVR procedures. All implants were performed under general anesthesia with a balloon-expandable Edwards Sapien stent-valve, and followed international guidelines on indications and techniques.
RESULTS: Procedural success rates ranged between 94% and 100%. Life-threatening apical bleeding occurred very rarely (0-5%), and its incidence decreased after the first series of implants. Stent-valve embolization was also rare, with a global incidence ranging from 0-2%, with evidence of improvement after the learning curve. Rates of valve malpositioning ranged from 0% to < 3%, whereas the risk of coronary obstruction ranged from 0% to 3.5%. Aortic root rupture and dissection were dramatic events reported in 0-2% of transapical cases. Stent-valve malfunction was rarely reported (1-2%), whereas the valve-in-valve bailout procedure for malpositioning, malfunctioning or severe paravalvular leak was reported in about 1.0-3.5% of cases. Sudden hemodynamic management and bailout procedures such as valve-in-valve rescue or cannulation for cardiopulmonary bypass were more effective when planned during the preoperative phase.
CONCLUSION: Despite attempts to avoid pitfalls, complications during transapical aortic valve procedures still occur. Preoperative strategic planning, including hemodynamic status management, alternative cannulation sites and bailout procedures, are highly recommended, particularly during the learning curve of this technique.

Entities:  

Mesh:

Year:  2013        PMID: 24151752

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  5 in total

Review 1.  Iatrogenic Acute Aortic Dissection in the Era of Minimally Invasive Cardiac Surgery - Experience of a Center and Review of Literature.

Authors:  Daniele De Viti; Pierpaolo Dambruoso; Paolo Izzo; Ilir Dhojniku; Pasquale Raimondo; Carmine Carbone; Domenico Paparella
Journal:  Braz J Cardiovasc Surg       Date:  2021-10-17

2.  The effects of positioning of transcatheter aortic valves on fluid dynamics of the aortic root.

Authors:  Elliott M Groves; Ahmad Falahatpisheh; Jimmy L Su; Arash Kheradvar
Journal:  ASAIO J       Date:  2014 Sep-Oct       Impact factor: 2.872

3.  Learning curves for transapical transcatheter aortic valve replacement in the PARTNER-I trial: Technical performance, success, and safety.

Authors:  Rakesh M Suri; Sa'ar Minha; Oluseun Alli; Ron Waksman; Charanjit S Rihal; Lowell P Satler; Kevin L Greason; Rebecca Torguson; Augusto D Pichard; Michael Mack; Lars G Svensson; Jeevanantham Rajeswaran; Ashley M Lowry; John Ehrlinger; Stephanie L Mick; E Murat Tuzcu; Vinod H Thourani; Raj Makkar; David Holmes; Martin B Leon; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2016-04-13       Impact factor: 5.209

Review 4.  Iatrogenic aortic dissection after minimally invasive aortic valve replacement: a case report.

Authors:  Mohamed Ehab Ramadan; Lamia Buohliqah; Juan Crestanello; James Ralston; David Igoe; Hamdy Awad
Journal:  J Cardiothorac Surg       Date:  2016-08-24       Impact factor: 1.637

Review 5.  Access Sites for TAVI: Patient Selection Criteria, Technical Aspects, and Outcomes.

Authors:  Luigi Biasco; Enrico Ferrari; Giovanni Pedrazzini; Francesco Faletra; Tiziano Moccetti; Francesco Petracca; Marco Moccetti
Journal:  Front Cardiovasc Med       Date:  2018-07-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.